Investing.com - Las acciones de Novo Nordisk (CSE:NOVOb) subieron fuertemente el lunes después de que la empresa de telesalud Hims Hers Health (NYSE:HIMS) retirara su píldora compuesta para bajar de p ...
Metsera said Novo Nordisk's new bid for the obesity biotech is "superior" to a revised offer from Pfizer, escalating a heated tussle over the startup between the two pharmaceutical giants. Novo ...
Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.
Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit ...
CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...
The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications. Novo Nordisk dropped the price for injectable Wegovy and ...
COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk's Frankfurt-listed shares rose 4.5% on Monday after telehealth firm Hims & Hers reversed its launch of a $49 compounded weight-loss pill over the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results